Wingor Biotech adheres to independent research and development and innovation, and has applied for more than 70 domestic and foreign patents in the field of cell and gene therapy, and has built a core technology platform with independent intellectual property rights.

The company has carried out a series of basic research and clinical translation explorations in the fields of stem cells, immune cells, and exosomes. While continuously optimizing existing cell technologies, it actively introduces internationally advanced gene editing technologies and promotes the research and development of new products through technology integration. It has developed a diversified product pipeline covering stem cells, immune cells, and exosomes, and established standardized preparation processes and a sound quality management system from sample collection, separation, culture to storage and transportation, achieving full process control.